Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity

Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity

Clinical and animal studies have demonstrated that chemotherapeutic doxorubicin (DOX) increases arterial stiffness, a predictor of cardiovascular risk. Despite consensus about DOX-impaired endothelium-dependent vasodilation as a contributing mechanism, some studies have reported conflicting results...

Full description

Bibliographic Details
Main Authors:	Matthias Bosman, Dustin N. Krüger, Kasper Favere, Callan D. Wesley, Cédric H. G. Neutel, Birgit Van Asbroeck, Owen R. Diebels, Bart Faes, Timen J. Schenk, Wim Martinet, Guido R. Y. De Meyer, Emeline M. Van Craenenbroeck, Pieter-Jan D. F. Guns
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	International Journal of Molecular Sciences
Subjects:	doxorubicin cardio-oncology arterial stiffness endothelial dysfunction vascular smooth muscle cell contraction non-selective cation channel
Online Access:	https://www.mdpi.com/1422-0067/22/23/12812

Similar Items

Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
by: Manrose Singh, et al.
Published: (2022-01-01)

Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide
by: A. A. Avagimyan
Published: (2022-06-01)

Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice.
by: Matthias Bosman, et al.
Published: (2023-01-01)

Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice
by: Matthias Bosman, et al.
Published: (2023-01-01)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
by: Vincenzo Quagliariello, et al.
Published: (2021-07-01)

Evaluation of an Ayurvedic polyherbal formulation (Sindhuvaradi agada) in Doxorubicin induced Cardiotoxicity- in wistar rats
by: Shrutika Subhash Karoshi, et al.
Published: (2018-01-01)

Evaluation of an Ayurvedic polyherbal formulation (Sindhuvaradi agada) in Doxorubicin induced Cardiotoxicity- in wistar rats
by: Shrutika Subhash Karoshi, et al.
Published: (2019-01-01)

The Metabolic Fingerprint of Doxorubicin-Induced Cardiotoxicity in Male CD-1 Mice Fades Away with Time While Autophagy Increases
by: Sofia Reis Brandão, et al.
Published: (2023-11-01)

Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy
by: Mária Lódi, et al.
Published: (2019-07-01)

Zymosan A Improved Doxorubicin‐Induced Ventricular Remodeling by Evoking Heightened Cardiac Inflammatory Responses and Healing in Mice
by: Guiwen Xu, et al.
Published: (2023-09-01)

New tirapazamine derivatives protect cardiomyocytes from doxorubicin toxicity
by: Korga Agnieszka, et al.
Published: (2020-03-01)

Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
by: Anchit Bhagat, et al.
Published: (2022-08-01)

Preparation of Cationic Amphiphilic Nanoparticles with Modified Chitosan Derivatives for Doxorubicin Delivery
by: Xiudong Liu, et al.
Published: (2021-11-01)

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin
by: Kevin Shee, et al.
Published: (2016-12-01)

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury
by: Qingling Zhang, et al.
Published: (2023-08-01)

Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy
by: Anis Askarizadeh, et al.
Published: (2023-03-01)

Cardioprotective Strategies for Doxorubicin-induced Cardiotoxicity: Present and Future
by: A. M. Chaulin, et al.
Published: (2022-03-01)

Inflammatory Reprogramming Mediates Changes in Three-Dimensional Strain Capacity and Cardiac Function in Beagle Dogs with Doxorubicin-Related Cardiomyopathy
by: Yifan Chen, et al.
Published: (2024-02-01)

In the Heart of Cardio-Oncology: The Targets and Biomarkers of Cardiotoxicity in Anticancer Drugs
by: Vera Marisa Costa
Published: (2022-11-01)

Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
by: Yichuan Jiang, et al.
Published: (2023-05-01)

Transferrin-Conjugated Polymeric Nanoparticle for Receptor-Mediated Delivery of Doxorubicin in Doxorubicin-Resistant Breast Cancer Cells
by: Zar Chi Soe, et al.
Published: (2019-02-01)

The effect of cyclic stretch on aortic viscoelasticity and the putative role of smooth muscle focal adhesion
by: Cédric H. G. Neutel, et al.
Published: (2023-08-01)

Cationic anticancer peptide L-K6-modified and doxorubicin-loaded mesoporous silica nanoparticles reverse multidrug resistance of breast cancer
by: Haiting Sun, et al.
Published: (2024-05-01)

Doxorubicin-related effects on cardiorespiratory function and body composition
by: Ashley J. Smuder
Published: (2024-02-01)

Histopathological effects of doxorubicin on kidneys in rats
by: I.A. Ali, et al.
Published: (2014-06-01)

Doxorubicin and Doxorubicin-loaded Nanoliposome Triggers Hepatocyte Cells Senescence through Accumulation of Inflammatory Factors and Activation of P53
by: Nazanin Rahmanian, et al.
Published: (2022-02-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Doxorubicin-Induced Cardiomyopathy: A Preliminary Study on the Cardioprotective Benefits of 7-Hydroxyflavanone
by: Nonhlakanipho F. Sangweni, et al.
Published: (2023-10-01)

Lipidomics application to explain acute cardiotoxicity induced by doxorubicin
by: Lubna Zuhair Abdul Karim, et al.
Published: (2019-12-01)

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
by: Sebahat Ulusan, et al.
Published: (2023-05-01)

Histopathological effects of doxorubicin on pancreas in male albino rats
by: I.A. Ali, et al.
Published: (2015-06-01)

Doxorubicin: The dogma and the bone
by: Jia Y. Wong, et al.
Published: (2016-02-01)

A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity
by: Katerina N. Panagiotaki, et al.
Published: (2017-11-01)

Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice
by: Ibrahim Y. Abdelgawad, et al.
Published: (2021-08-01)

Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
by: Quagliariello V, et al.
Published: (2020-07-01)

Dynamics of pathological changes of myocardial structures of rats under administration of doxorubicin
by: А. G. Rodinskij, et al.
Published: (2015-04-01)

Simultaneous determination of doxorubicin and its dipeptide prodrug in mice plasma by HPLC with fluorescence detection
by: Jing Han, et al.
Published: (2016-06-01)

Application of Optical Methods for Determination of Concentration of Doxorubicin in Blood and Plasma
by: Tomasz Sikora, et al.
Published: (2022-01-01)

Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA
by: Reza Hajian, et al.
Published: (2017-02-01)

Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)